CRBP
$1.80
Corbus Pharma
($.17)
(8.63%)
CRBP
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.40)
Revenue:  $3.42 Mil
Thursday
Nov 5
7:05 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRBP reports earnings?
Beat
Meet
Miss

Where is CRBP's stock price going from here?
Up
Flat
Down
Stock chart of CRBP
Analysts
Summary of analysts' recommendations for CRBP
Score
Grade
Pivots
Resistance
$2.30
$2.18
$1.99

$1.88

Support
$1.69
$1.58
$1.39
Tweet
Growth
Description
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesSeattle GeneticsBluebird BioQiagen N.V.RepligenSangamo TherapeuticsBio-Techne